image

Authoritative Independent Monthly Share Selections Using Technical & Fundamental Analysis

Latest issue now available

SIGN UP NOW
Updates

Alliance Pharma

October 2010

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • APH
  • Price:
  • 37p
After strong interims, shares in speciality pharmaceutical firm Alliance Pharma have soared to 37p, nicely ahead of our main recommendation price of 20.75p. Pretax profit rose a full 166% to £7.7m on turnover that rose 77% to £23.4m. Eps rose 98% to 2.5p. Gross margins shifted up sharply from 53% to 61% reflecting a change in mix towards higher margin products. Encouragingly, despite funding around £7m of the acquisition of Cambridge Labs with debt the group ended the period with slightly lower net debt than a year ago. Net debt to EBITDA fell from 2 times to just 1.3, while it also reduced its outstanding convertible loan stock from £7.5m to £5m. The strong performance reflected not only first time contributions from ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Related Articles

Alliance Pharma (July 2013)
Alliance Pharma - Acquires new products (September 2012)
Alliance Pharma (June 2012)
Alliance Pharma (November 2011)
Alliance Pharma - Cambridge Labs nehind its growth (June 2011)
Alliance Pharma (August 2010)
Alliance Pharma - Trading ahead of expectations (July 2010)
Alliance Pharma - Gain reaches 75% in five months (May 2010)
Alliance Pharma - Substantial eps enhancing acquisition (March 2010)
Alliance Pharma - Beats expectations again (February 2010)
Alliance Pharma - Branded pharmaceuticals firm going great guns but cheap on PE of 6.7 (December 2009)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X